+ Show All | Hide All
NASRAT HAKIM President Chief Executive Officer
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S. Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.
Mr. Hakim s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
CARTER WARD Chief Financial Officer
Carter Ward joined Elite in July of 2009 as Chief Financial Officer. Mr. Ward is a certified public accountant, graduated summa cum laude from Long Island University, Brooklyn, NY. For most of the past fifteen years, Mr. Ward s experience has been in the generic pharmaceutical industry, most recently filling multiple finance and supply chain leadership roles with Actavis Group and its U.S. subsidiary, Amide Pharmaceuticals. Earlier in his career, he was the Chief Financial Officer for Positive Healthcare/Ceejay Healthcare, a U.S.-Indian joint venture engaged in the manufacture and distribution of generic pharmaceuticals and nutraceuticals in India. Mr. Ward began his career in public accounting with KPMG.
G. KENNETH SMITH, J.D. PH.D. Vice President of Legal
Ken Smith has served as Elite s Vice President of Legal since October 2014. Prior to joining Elite, Dr. Smith previously held the positions of Chief Intellectual Property Counsel for Alpharma, Inc. and before that Head of North American Intellectual Property for Sanofi Aventis. In both positions, Dr. Smith had global responsibility for all intellectual property issues related to multiple business units involved with various technologies including branded products, animal health products, active pharmaceutical ingredients, generic drugs, and vaccines. Dr. Smith also brings extensive background and knowledge in the area of abuse deterrent intellectual property. Dr. Smith has a Ph.D. in Biochemistry from University of Houston, an M.B.A from Lehigh University, and a J.D. from the University of Houston.
DOUG PLASSCHE Executive Vice President of Operations
Doug Plassche, a Certified Six Sigma Black Belt, joined Elite in August 2013 and brings with him more than 23 years of pharmaceutical industry experience. From 2009 to 2013, Mr. Plassche was employed by Actavis as Managing Director of the New Jersey Solid Oral Dose Operations, overseeing 450 employees and the production of more than 100 products. From 2007 to 2009, Mr. Plassche was Senior Director of Manufacturing for PAR Pharmaceuticals overseeing 200 employees and the production of more than 70 products. From 1990 2007, he was employed by Schering-Plough progressing steadily through multiple disciplines, locations and technical operations sectors with increasing levels or responsibility.
BARBARA ELLISON Vice President of Quality Operations and Regulatory Affairs
Barbara Ellison joined Elite in March 2014 as Vice President, Quality Operations Regulatory Affairs. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite s quality and regulatory functions including the Company s Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite s senior leadership team, reporting directly to Nasrat Hakim, Elite s President and Chief Executive Officer.
Prior to joining Elite, Ellison served as Director of Global Quality for the Cell Systems Division of Life Technologies, overseeing the quality and regulatory compliance at ten manufacturing sites worldwide and overseeing 135 people. Before then, Ms. Ellison was Vice President of Quality for West Pharmaceutical Services and Site Head of Quality Operations for Alpharma (now Actavis). She also served in senior level positions with Novartis as Head of Compliance, Warner Lambert as Director of Quality Operations and Regulatory Compliance/Quality Assessment. Ms. Ellison holds a B.S. in Chemistry and Mathematics from Central Connecticut State University, New Britain, CT.
CHRIS DICK Head of Development
Chris Dick joined Elite in November 2002 as Vice President of Business Development. Since August 2013, Mr. Dick has served as Head of Development. During his tenure at Elite, Mr. Dick has served in various capacities including Executive Vice President of Corporate Development, President, Chief Operating Officer, acting Chief Executive Officer and Board Director. Prior to joining Elite, Mr. Dick served as Director of Business Development for Elan Drug Delivery, Inc. responsible for licensing and business development of Elan’s portfolio of drug delivery technologies. From 1978 to 1999, he held various business and technical positions at FMC Corporation which included responsibility for business development and marketing for EnTec™, a drug delivery business unit within FMC Corporation’s Pharmaceutical Division, and marketing for its pharmaceutical functional coatings product line. Mr. Dick holds an M.B.A. from the Stern School of Business, New York University, and a B.S. and M.S. in Chemical Engineering from Cornell University.
DIANNE WILL Vice President of Investor Relations and Corporate Affairs
Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for management team changes, proxy fights, crisis management and IPOs.